Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valganciclovir prophylaxis vs pre-emptive therapy for CMV after kidney transplantation
2005-004695-20Phase 3Completed
- Sponsor
- Roche
- Start
- Jan 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of valganciclovir in cytomegalovirus disease (CMV) and kidney allograft rejection (2 arms), sponsored by Roche. Primary endpoints: Incidence of CMV disease within 12 months and Incidence of active CMV infection. Started Jan 2006; status: completed.
02
Drugs
valganciclovir
03
Conditions
cytomegalovirus disease (CMV)kidney allograft rejection
Beyond the preview
Go deeper on 2005-004695-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004695-20.